Replies to post #7982 on Marker Therapeutics Inc (MRKR)

[Rkmatters]

You're correct. They released the primary endpoint. They were on time.

http://www.tapimmune.com/news/tapimmune-reports-robust-immune-responses-generated-in-19-of-20-evaluable-her2neu-breast-cancer-patients/

The secondary endpoint on on time to progression is still aging (2.5 years), not sure when they reach 30 month mark. Need to figure how much time elapsed to that June PR on its primary endpoint. I believe secondary is next year's.